Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Iparomlimab and Tuvonralimab Injection”

27 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 27 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07131345
What this trial is testing

Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant Mesothelioma

Who this might be right for
Malignant MesotheliomaMesothelioma
National Cancer Center, China 55
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07131501
What this trial is testing

A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma

Who this might be right for
Hepatocellular CarcinomaImmunotherapyPreoperative+2 more
The First Affiliated Hospital with Nanjing Medical University 48
Testing effectiveness (Phase 2)Looking for participantsNCT07110064
What this trial is testing

QL1706+Lenvatinib+AG Regimen as First-line Treatment for Advanced Metastatic Pancreatic Cancer

Who this might be right for
Advance Pancreatic Cancer
Du Juan 80
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07263360
What this trial is testing

Iparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer

Who this might be right for
BTC
Tianjin Medical University Cancer Institute and Hospital 29
Testing effectiveness (Phase 2)Looking for participantsNCT07289997
What this trial is testing

Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC)

Who this might be right for
AFP Gastric or Gastroesophageal Junction AdenocarcinomaPD-1/CTLA-4AFPGC+1 more
Hebei Medical University Fourth Hospital 39
Testing effectiveness (Phase 2)Looking for participantsNCT07392346
What this trial is testing

Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer

Who this might be right for
Gastric Cancer Adenocarcinoma Metastatic
Dai, Guanghai 68
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07135804
What this trial is testing

Iparomlimab and Tuvonralimab Injection for Untreated Locally Advanced Nasopharyngeal Carcinoma

Who this might be right for
Locally Advanced Nasopharyngeal Squamous Cell Carcinoma
Second Affiliated Hospital of Nanchang University 45
Testing effectiveness (Phase 2)Looking for participantsNCT07327788
What this trial is testing

QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT

Who this might be right for
Hepatecellular CarcinomaRALOX-HAIC（Hepatic Arterial Infusion Chemotherapy With Raltitrexed and OxaliplatinBevacizumab+3 more
Nanfang Hospital, Southern Medical University 38
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07349225
What this trial is testing

Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy and Sequential Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer

Who this might be right for
ES-SCLC
The Second Affiliated Hospital of Dalian Medical University 46
Not applicableNot Yet RecruitingNCT07046780
What this trial is testing

A Multicenter, Prospective, Non-Interventional Real-World Study of Iparomlimab and Tuvonralimab Injection (QL1706) in the Treatment of Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Solid Tumor CancerMetastatic Solid TumorsLocally Advanced
PENG YUAN 90
Testing effectiveness (Phase 2)Looking for participantsNCT07232654
What this trial is testing

Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC

Who this might be right for
LOCALLY ADVANCED CERVICAL CANCERS
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 30
Testing effectiveness (Phase 2)Looking for participantsNCT06951997
What this trial is testing

QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer

Who this might be right for
Metastatic Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital 33
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06958484
What this trial is testing

Iparomlimab and Tuvonralimab Injection (QL1706) Combined With Bevacizumab for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma (HCC) With High Risk of Recurrence

Who this might be right for
HCC - Hepatocellular CarcinomaAdjuvant Treatment
The Affiliated Hospital of Xuzhou Medical University 60
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07271602
What this trial is testing

Randomized, Controlled Trial of QL1706 Plus Chemotherapy and Quad Shot for Driver Gene-negative Advanced Non-small Cell Lung Cancer.

Who this might be right for
Non Small Cell Lung CancerImmunotherapyRadiotherapy+1 more
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 104
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07128251
What this trial is testing

A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)

Who this might be right for
Hepatocellular Carcinoma (HCC)ImmunotherapyPD-1+2 more
Anhui Provincial Hospital 47
Large-scale testing (Phase 3)Looking for participantsNCT06749899
What this trial is testing

QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.

Who this might be right for
Nasopharyngeal Cancinoma (NPC)Nasopharyngeal Cancer
Sun Yat-sen University 580
Very early researchLooking for participantsNCT07343791
What this trial is testing

Efficacy and Safety Study of DC-CIK Cell Therapy Combined With Epaloliposide, Vortexil, and Regorafenib as Third-line Treatment for Advanced Colorectal Cancer.

Who this might be right for
DC-CIK TreatmentRegorafenibColorectal Cancer+2 more
JIANG LONGWEI 14
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07372079
What this trial is testing

Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy

Who this might be right for
Breast CancerNeoadjuvant TherapyImmune Checkpoint Inhibitors+1 more
Tianjin Medical University Cancer Institute and Hospital 40
Not applicableNot Yet RecruitingNCT07115550
What this trial is testing

A Single-center, Single-arm, Phase II Clinical Study of Iparomlimab and Tuvonralimab Injection Combined With Regorafenib in the Treatment of Advanced Second-line or Above Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma (HCC)
Huai'an First People's Hospital 24
Testing effectiveness (Phase 2)Looking for participantsNCT07099274
What this trial is testing

Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular Carcinoma

Who this might be right for
HCC
Tianjin Medical University Cancer Institute and Hospital 29
Load More Results